Lysergic acid diethylamide

Emerge (Phase 3 MDD) enrollment complete; topline data anticipated in late 2Q 2026 Voyage (Phase 3 GAD) approximately 80% enrolled; no change in sample size required; topline readout anticipated in early 3Q 2026 Panorama (Phase 3 GAD) enrollment on track; topline readout expected in 2H 2026 $411.6 million in cash, cash equivalents and investments as of December 31, 2025 expected to fund operations into 2028 Conference call scheduled today at 4:30 p.m. EST NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today reported its full-year 2025 financial results and provided business updates. “We are proud of the strong execution and momentum across our organization, following a year of significant progress in our comprehensive development programs for DT120 ODT,” said Rob Barrow, Chief Executive Officer of Definium Therapeutics. “With our first Phase 3 MDD trial, Emerge, now fully enrolled and advancing toward topline data sooner than anticipated, and our Phase 3 GAD studies, Voyage and Panorama, rapidly progressing toward enrollment completion, 2026 represents a monumental year for Definium. Each of these pivotal readouts represents an important catalyst opportunity to move DT120 ODT one step closer to delivering on its best-in-class potential in both MDD and GAD. We remain committed to precise science and our ambitious view of the potential to deliver meaningful improvements for patients, reinforce our leadership in mental health innovation, and drive long-term shareholder value.” Business Updates Completed equity financing in 4Q 2025 totaling approximately $259 million in gross proceeds, before deducting underwriting discounts and commissions and offering expenses payable by the Company, bringing in multiple new institutional investors, and extending the Company’s cash runway into 2028. Published full study results in the Journal of the American Medical Association from the Company’s randomized, placebo-controlled Phase 2b trial evaluating a single dose of DT120 across four dose levels in patients with moderate to severe generalized anxiety disorder (GAD). DT120 has received FDA Breakthrough Designation for GAD. Further strengthened the leadership team with the appointments of Brandi L. Roberts as Chief Financial Officer and Matt Wiley as Chief Commercial Officer. Expanded Board of Directors with appointment of Roger Adsett in January 2026. Mr. Adsett is a highly accomplished biopharmaceutical executive with more than two decades of experience leading landmark drug launches, scaling global commercial organizations, and helping companies establish leadership positions within their therapeutic areas, including specialty, rare disease, and primary care markets. He currently serves as Chief Operating Officer of Insmed. Company to host Investor and Analyst Day on April 22, 2026, to discuss program updates and the commercial opportunity for DT120 orally disintegrating tablet (ODT) (lysergide tartrate). Program Updates and Anticipated Milestones The program for DT120 ODT (lysergide tartrate) consists of four pivotal Phase 3 studies, two in GAD and two in major depressive disorder (MDD). Each study is comprised of two parts: Part A, a 12-week, randomized, double-blind, placebo-controlled, parallel group assessing the efficacy and safety of DT120 ODT versus placebo, and Part B, a 40-week open-label extension period. The primary endpoint in the GAD studies is the change from baseline in Hamilton Anxiety Scale (HAM-A) score at Week 12 between DT120 ODT 100 µg and placebo; and in the MDD studies the change from baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) score at Week 6 between DT120 ODT 100 µg and placebo. DT120 ODT (lysergide tartrate) for MDD Emerge : study is fully enrolled with 149 patients randomized 1:1 to receive DT120 ODT 100 µg or placebo. Topline data are anticipated in late 2Q 2026. Ascend : initial sites have been activated, and study initiation has been accelerated with first patient dosing anticipated by early 2Q 2026. The trial is expected to enroll approximately 175 participants randomized 2:1:2 to receive DT120 ODT 100 µg, DT120 ODT 50 µg control, or placebo. DT120 ODT (lysergide tartrate) for GAD Voyage : study enrollment is approximately 80% complete and is expected to conclude in the coming weeks. Topline data are anticipated in early 3Q 2026. The protocol-specified blinded sample size re-estimation is complete, requiring no increase in enrollment. Voyage is expected to enroll approximately 200 participants in the U.S. randomized 1:1 to receive DT120 ODT 100 µg or placebo. Panorama : study enrollment on track with topline data anticipated in 2H 2026. Panorama is expected to enroll approximately 250 participants, in the U.S. and Europe, randomized 2:1:2 to receive DT120 ODT 100 µg, DT120 ODT 50 µg control, or placebo. Further enrollment updates and the outcome of the protocol-specified, blinded sample size re-estimation is planned to be provided at Investor and Analyst Day on April 22, 2026. DT402 (R(-)-MDMA) for Autism Spectrum Disorder (ASD) Following the completion of its single-ascending dose Phase 1 study of DT402 in adult healthy volunteers, the Company initiated a Phase 2a study in 4Q 2025. The study is a single-dose, open-label study assessing early signals of efficacy of DT402 in treating core socialization and communication symptoms of ASD in up to 20 adult participants. The objectives and endpoints of the study are designed to characterize the pharmacodynamics and clinical effects of DT402 in adults with ASD, including on multiple functional biomarkers. Initial data from the Phase 2a study is anticipated in 2026. 2025 Financial Results Cash, Cash Equivalents and Investments. As of December 31, 2025, Definium Therapeutics had cash, cash equivalents and investments of $411.6 million compared to $273.7 million as of December 31, 2024. Based on the Company’s current operating plan and anticipated milestones, the Company believes that its cash, cash equivalents and investments as of December 31, 2025 will be sufficient to fund the Company’s operations into 2028. Research and Development (R&D). R&D expenses were $117.7 million for the year ended December 31, 2025, compared to $65.3 million for the year ended December 31, 2024, an increase of $52.4 million. The increase was primarily due to increases of $44.7 million in DT120 program expenses, $9.3 million in internal personnel costs reflecting expanded research and development capabilities, and $0.4 million in preclinical and other program expenses, partially offset by a $2.0 million reduction in DT402 program expenses. General and Administrative (G&A). G&A expenses were $48.6 million for the year ended December 31, 2025, compared to $38.6 million for the year ended December 30, 2024, an increase of $10.0 million. The increase was primarily due to increases of $6.0 million in professional services and pre-commercialization activities, $3.6 million in personnel-related expenses, $0.7 million in directors’ deferred share unit expenses and $0.5 million in other miscellaneous administrative expenses, offset by a reduction of $0.8 million in legal and patent-related expenses. Conference Call and Webcast Reminder Definium Therapeutics management will host a webcast at 4:30 p.m. EST today to provide a corporate update and review the Company’s full-year 2025 financial results and business highlights. Listeners can register for the webcast via this link . Analysts wishing to participate in the question-and-answer session should use this link . A replay of the webcast will be available via the Investor Relations section of the Definium Therapeutics website, ir.definiumtx.com, and archived for at least 30 days after the webcast. Those who plan on participating are advised to join 15 minutes prior to the start time. About DT120 Orally Disintegrating Tablet (ODT) DT120 ODT (lysergide tartrate) is an ergoline derivative belonging to the group of classic serotonergic psychedelics which acts as a partial agonist at specific serotonin receptors (human serotonin-2A (5-HT2A) receptors). DT120 ODT is Definium’s proprietary and pharmaceutically optimized formulation of LSD. DT120 ODT is an advanced formulation incorporating Catalent’s Zydis ® ODT fast-dissolve technology, which is designed to deliver several unique advantages, such as faster absorption and faster onset of transient cognitive, perceptual, and affective changes, improved bioavailability, and lower incidence of gastrointestinal side effects. Definium is developing DT120, the tartrate salt form of lysergide, for generalized anxiety disorder (GAD), major depressive disorder (MDD), and is exploring its potential applications in other serious brain health disorders. About DT402 DT402 is the Company’s proprietary form of R(-)-MDMA (rectus-3,4 methylenedioxymethamphetamine), being developed for the treatment of core symptoms of autism spectrum disorder (ASD). MDMA is a synthetic molecule that is often referred to as an empathogen because it is reported to increase feelings of connectedness and compassion. Preclinical studies of R(-)-MDMA demonstrate its acute pro-social and empathogenic effects, while its diminished dopaminergic activity suggest that it has the potential to exhibit less stimulant activity, neurotoxicity, hyperthermia and abuse liability compared to racemic MDMA or the S(+)-enantiomer. About Definium Therapeutics The mission of Definium Therapeutics is to forge a new era of psychiatry by applying scientific rigor to psychedelics, with the goal of developing accessible treatments that unlock healing at scale. Guided by a recognition that patients deserve more than better, Definium is relentlessly advancing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders. By turning evidence into impact, Definium aims to change the trajectory of today’s mental health care crisis and enable a healthier future. Headquartered in New York, Definium Therapeutics trades on Nasdaq under the symbol DFTX. For more information, visit and follow Definium Therapeutics on Instagram , LinkedIn and X . Forward-Looking Statements Certain statements in this news release related to the Company constitute "forward-looking information" within the meaning of applicable securities laws and are prospective in nature. Forward-looking information is not based on historical facts, but rather on current expectations and projections about future events and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. These statements generally can be identified by the use of forward-looking words such as "will", "may", "should", "could", "intend", "estimate", "plan", "anticipate", "expect", "believe", "potential" or "continue", or the negative thereof or similar variations. Forward-looking information in this news release includes, but is not limited to, statements regarding the Company’s anticipated topline readout (Part A results) for the Phase 3 Voyage study of DT120 ODT in GAD in early 3Q 2026; the Company’s anticipated topline readout (Part A results) for the Phase 3 Panorama study for DT120 ODT in GAD in the second half of 2026; the Company’s anticipated topline readout (Part A results) for the Phase 3 Emerge study for DT120 ODT in MDD in late 2Q 2026; the Company’s plans to dose the first patient the Phase 3 Ascend study of DT120 ODT in MDD by early 2Q; the Company’s expectations regarding the enrollment for each of the Voyage, Panorama and Ascend studies, including the Company’s belief that Voyage will complete enrollment in the coming weeks; the Company’s beliefs regarding potential benefits of its product candidates; the Company’s expectations regarding enrollment in its Phase 2a study of DT402 for the treatment of ASD; the Company’s anticipated initial data readout for its Phase 2a study of DT 402 for the treatment of ASD in 2026; the Company’s expectation that its cash, cash equivalents and investments will fund operations into 2028; and potential additional indications for DT120 ODT and DT402. There are numerous risks and uncertainties that could cause actual results and the Company's plans and objectives to differ materially from those expressed in the forward-looking information, including history of negative cash flows; limited operating history; incurrence of future losses; availability of additional capital; compliance with laws and regulations; legislative and regulatory developments, including decisions by the Drug Enforcement Administration and states to reschedule any of our product candidates, if approved, containing Schedule I controlled substances, before they may be legally marketed in the U.S.; difficulty associated with research and development; risks associated with clinical studies or studies; heightened regulatory scrutiny; early stage product development; clinical study risks; regulatory approval processes; novelty of the psychedelic inspired medicines industry; ability to maintain effective patent rights and other intellectual property protection; as well as those risk factors discussed or referred to herein and the risks, uncertainties and other factors described in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2025 under headings such as "Special Note Regarding Forward-Looking Statements," and "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" and other filings and furnishings made by the Company with the securities regulatory authorities in all provinces and territories of Canada which are available under the Company's pro SEDAR+ at and with the U.S. Securities and Exchange Commission on EDGAR at . Except as required by law, the Company undertakes no duty or obligation to update any forward-looking statements contained in this release as a result of new information, future events, changes in expectations or otherwise. Definium Therapeutics, Inc. Consolidated Balance Sheets December 31, (in thousands, except share amounts) 2025 2024 Assets Current assets: Cash and cash equivalents $ 257,837 $ 273,741 Short-term investments 153,756 — Prepaid and other current assets 7,727 7,879 Total current assets 419,320 281,620 Goodwill 19,918 19,918 Other non-current assets 862 613 Total assets $ 440,100 $ 302,151 Liabilities and Shareholders’ Equity Current liabilities: Accounts payable $ 5,347 $ 2,010 Accrued expenses 20,446 12,829 2022 USD Financing Warrants 40,905 24,010 Total current liabilities 66,698 38,849 Credit facility, long-term 40,579 21,854 Other non-current liabilities 496 — Total liabilities 107,773 60,703 Commitments and contingencies Shareholders' equity: Common shares, no par value, unlimited authorized as of December 31, 2025 and 2024, respectively; 98,776,265 and 75,100,763 issued and outstanding as of December 31, 2025 and 2024, respectively — — Additional paid-in capital 913,914 639,508 Accumulated other comprehensive income 1,085 819 Accumulated deficit (582,672 ) (398,879 ) Total shareholders' equity 332,327 241,448 Total liabilities and shareholders' equity $ 440,100 $ 302,151 Definium Therapeutics, Inc. Consolidated Statements of Operations and Comprehensive Loss Year Ended December 31, (in thousands, except share and per share amounts) 2025 2024 Operating expenses: Research and development $ 117,665 $ 65,297 General and administrative 48,644 38,619 Total operating expenses 166,309 103,916 Loss from operations (166,309 ) (103,916 ) Other income/(expense): Interest income 10,960 11,558 Interest expense (5,482 ) (2,283 ) Foreign exchange loss, net (131 ) (638 ) Change in fair value of 2022 USD Financing Warrants (22,831 ) (15,941 ) Gain on extinguishment of contribution payable — 2,541 Total other expense, net (17,484 ) (4,763 ) Net loss (183,793 ) (108,679 ) Other comprehensive loss Unrealized gain on investments 330 — Gain/(loss) on foreign currency translation (64 ) 476 Comprehensive loss $ (183,527 ) $ (108,203 ) Net loss per common share, basic and diluted $ (2.06 ) $ (1.54 ) Weighted-average common shares, basic and diluted 89,327,608 70,461,067 Contacts Investors: Gitanjali Jain VP, Head of Investor Relations ir@definiumtx.com Media: media@definiumtx.com

· Dr Papapetropoulos brings more than 20 years of CNS-focused biopharma leadership, including C-suite roles at Neuphoria Therapeutics (Nasdaq: NEUP), Acadia Pharmaceuticals (Nasdaq: ACAD), Vigil Neuroscience (Nasdaq: VIGL), Biogen, Allergan, and Pfizer · Track record includes more than 20 IND filings, multiple NDA/BLA submissions, and multiple CNS product approvals and launches worldwide · Appointment aligns with key milestones, including the recent publication of Phase 1 PoC data and the upcoming NBX-100 Phase 1 PK/PD study, supporting the Company’s continued expansion in neuropsychiatry · Neurala’s lead candidates NBX-100 (oral, medium-duration) and NBX-200 (intranasal, short-acting) are engineered for scalable, regulated medical use in substance use and depressive disorders MELBOURNE, Australia, February 24, 2026 — Neurala Biosciences (Neurala), a clinical-stage biotechnology company developing second-generation psychedelic neuromedicines for mental health and addiction, today formally announced the appointment of Spyros Papapetropoulos, MD, PhD, as Board Chair and Director. The appointment strengthens Neurala’s board with deep US regulatory and commercial drug development expertise as the company advances its proprietary DMT–harmala product candidates toward Phase 2 efficacy studies. Dr Papapetropoulos is a board-certified neurologist and neuroscientist with more than 20 years of leadership in CNS drug discovery and development. He served as President and Chief Executive Officer of Neuphoria Therapeutics, Inc. (Nasdaq: NEUP) until December 2025, and continues as a board director. Previously, he held senior executive roles including Chief Development Officer at Acadia Pharmaceuticals (Nasdaq: ACAD), Chief Medical Officer at Vigil Neuroscience (Nasdaq: VIGL), CEO at SwanBio Therapeutics, and EVP of Research & Development and Chief Medical Officer at Cavion, which was subsequently acquired by Jazz Pharmaceuticals. Dr Papapetropoulos has also held leadership positions at Biogen, Allergan, Pfizer, and Teva Pharmaceuticals. He serves as Chairman of Lipocine, Inc. (Nasdaq: LPCN) and is founder of Phragma Therapeutics. Across these roles, he has led numerous IND, NDA, and BLA submissions, contributing to multiple CNS product approvals and global launches. Dr Papapetropoulos has authored more than 170 peer-reviewed publications and contributed to patents, capital raises, strategic partnerships, and M&A transactions across the CNS sector. “Neurala’s second-generation platform represents a compelling scientific and commercial opportunity in a category attracting major strategic interest,” said Dr Papapetropoulos. “The published clinical data demonstrate that a precision multi-alkaloid approach can deliver a robust therapeutic psychedelic experience, and the proprietary refinements in NBX-100 and NBX-200 position these candidates to compete effectively against both established and emerging programs. I look forward to contributing clinical, regulatory and commercial development expertise as the company enters its next phase of clinical advancement.” Clinical momentum and upcoming milestones The appointment follows a period of significant progress for Neurala, including the recent publication of Phase 1 proof-of-concept data in Scientific Reports , a Nature Portfolio journal. The study demonstrated that Neurala’s standardised DMT–harmala formulation achieved acute effect scores exceeding those reported in prior psilocybin and LSD studies on validated measures. Neurala is now advancing two differentiated product candidates derived from its proprietary chemistry platform: NBX-100, a medium-duration oral formulation for substance use disorders including alcohol use disorder, and NBX-200, a short-acting intranasal formulation for chronic depressive illness. The NBX-100 Phase 1 PK/PD study at CMAX Clinical Research in Adelaide is expected to commence shortly, with the GMP drug product released, ethics approval granted, and all contracts in place. A $2 million government-funded Phase 2a efficacy study will commence once Phase 1 pharmacokinetic data are available to inform dose selection. “Spyros brings deep CNS development experience at a key stage in our clinical progression,” said Dr Daniel Perkins, Chief Executive Officer and co-founder of Neurala Biosciences. “His track record of advancing programs from early development through to product approval and commercial launch, across smaller biotechnology and large pharmaceutical environments, will support disciplined execution as we advance our second-generation candidates toward later-stage studies, while also strengthening our position for future capital raising and global expansion, with an initial strategic focus on the United States.” About Neurala Biosciences Neurala Biosciences is a clinical-stage biotechnology company developing second-generation psychedelic neuromedicines for mental health and addiction. The company’s proprietary DMT–harmala chemistry platform enables unique flexibility to develop products with varying duration and intensity pro optimised for the needs of specific clinical indications. Neurala’s lead candidates, NBX-100 and NBX-200, are being developed for substance use and depressive disorders. The company has received seed funding from University of Melbourne commercialisation funds Tin Alley Ventures and the Genesis Pre-Seed Fund, with substantial non-dilutive grant support from the Australian Government. Development partners include CSIRO, IDT Australia, Monash Medicines Innovation Centre, and Eurofins. For more information, visit . About Spyros Papapetropoulos, MD, PhD Dr Papapetropoulos is a board-certified neurologist and neuroscientist with more than 20 years of leadership in CNS drug discovery and development. He has held C-suite and senior leadership roles at multiple Nasdaq-listed and global pharmaceutical companies, overseeing programs spanning small molecules, biologics, and gene therapies, with a proven track record of disciplined portfolio management and strategic optimization through complex clinical readouts. Dr Papapetropoulos trained in movement disorders neurology at the National Hospital for Neurology and Neurosurgery in London and held faculty positions at the University of Miami School of Medicine. He is the author of Mind Odyssey: A Doctor's Guide to Training Your Brain for Purpose, Balance, and Fulfillment (Advantage Media Group, 2026), and has authored more than 170 peer-reviewed publications. Media & Investor Contact media@neurala.co